Loading organizations...
NeuroBionics is a neurotechnology company developing advanced implantable bioelectronic devices. Its focus is on neural interface technology, utilizing innovations from textile and telecommunications industries to create next-generation solutions. The company's technical approach integrates bioelectronics seamlessly with the human body, providing precision bioelectronic medicine.
Founder details and the precise genesis of NeuroBionics are not publicly available in accessible snippets. The company's foundation likely arose from recognizing the need for improved interfaces between neural systems and electronic implants, aiming to address critical unmet needs in neurological care through advanced engineering.
Products from NeuroBionics are intended for patients suffering from neurological disorders such as Parkinson's disease and epilepsy, where bioelectronic intervention holds therapeutic promise. The company’s long-term vision is to advance human health through pioneering bioelectronic medicine, striving to significantly improve patient outcomes via neural interface technology.
NeuroBionics has raised $6.0M across 1 funding round.
NeuroBionics has raised $6.0M in total across 1 funding round.
NeuroBionics has raised $6.0M across 1 funding round. Most recently, it raised $6.0M Series A in December 2004.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2004 | $6M Series A | — | JAZZ Venture Partners, Osage University Partners | Announced |
NeuroBionics is a biotech startup founded in 2023, headquartered in Somerville, Massachusetts, specializing in precision bioelectronic medicine.[1][2][5] The company develops minimally invasive implantable neural devices using hair-thin, flexible, multifunctional fibers that record and stimulate neural activity, deliver drugs, ablate tissue, and enable endovascular delivery—targeting conditions like Parkinson's disease, essential tremor, epilepsy, and depression.[1][2][3] These devices serve patients with neurological disorders, neuroscientists, and pharmaceutical researchers, solving the problem of invasive brain surgeries by enabling stent-like procedures that broaden access to life-changing neuromodulation therapies while reducing environmental impact through efficient manufacturing.[2][3][4] With 7 employees and early traction via an SBIR Phase I grant ($254,456), NeuroBionics shows promising growth in the $240M neuroscience research and $600M drug screening markets.[1][4]
NeuroBionics was founded in 2023 by MJ Antonini (CEO) and Nicki Driscoll (CTO), both with over a decade of experience developing neural interfacing tools in MIT's Anikeeva lab.[2][5] Their idea emerged from a decade of MIT research on flexible bioelectronic fibers, inspired by personal family connections to neurological disorders—MJ witnessed unmet patient needs during medical training.[5] A pivotal moment came as they collaborated on fiber technology for less-invasive neuromodulation, leading them to spin out NeuroBionics from Greentown Labs to commercialize it.[2][5] Early traction includes an SBIR Phase I award for their OmniFiber probe, validating multifunctional capabilities for neuroscience research.[4]
NeuroBionics stands out in neural interfacing through its innovative fiber technology and minimally invasive approach:
NeuroBionics rides the bioelectronic medicine wave, merging neuroscience with flexible electronics to shift from invasive implants to endovascular neuromodulation—a trend accelerated by advances in MIT-derived fiber tech and rising demand for Parkinson's/epilepsy treatments.[1][3][5] Timing is ideal amid growing neurotech markets ($240M research, $600M pharma screening) and regulatory support like SBIR funding, fueled by aging populations and post-pandemic focus on minimally invasive care.[4] Market forces favoring it include biotech's push for sustainable manufacturing and endovascular innovations (e.g., stents), positioning NeuroBionics to influence the ecosystem by enabling broader clinical trials, drug screening, and therapy access—potentially transforming how startups and pharma interface with the nervous system.[2][4]
NeuroBionics is poised to scale from research tools like OmniFiber/IO fiber to clinical evStim devices, leveraging SBIR momentum for Phase II trials and partnerships in pharma/neurotech.[4] Trends like AI-driven neural mapping and sustainable biotech will shape its path, amplifying minimally invasive therapies amid a $multi-billion neuromodulation market. Its influence may evolve from lab innovator to ecosystem leader, democratizing bioelectronics and improving millions of lives—echoing its mission to seamlessly integrate tech with the human body for precision medicine.[5]
NeuroBionics has raised $6.0M in total across 1 funding round.
NeuroBionics's investors include Jazz Venture Partners, Osage University Partners.